基于脏在芯片上的脏的基础上,研究kaemperide在高尿血症中的潜在应用
Xinyu Song1, Lili Zhao2, Yingying Tian2
1The Second School of Clinical Medicine, Binzhou Medical University, Yantai, Shandong 264003, China.
Lab on a chip
|May 29, 2025
概括
凯姆佩里德在治疗高尿血症 (HUA) 中表现有前途,HUA是一种与脏问题相关的代谢疾病. 这种天然的黄类化合物改善尿酸分泌,并向URAT1转运体,提供了一种新的治疗途径.
科学领域:
- 生物医学工程 生物医学工程
- 药理学 药理学是指药理学的学科.
- 代谢疾病 代谢疾病
背景情况:
- 超尿血症 (HUA) 是一种代谢状况,其特征是血清尿酸 (SUA) 升高.
- HUA与包括痛风,高血压和慢性病在内的重大并发症有关.
- 对HUA的有效治疗策略仍然是积极研究的领域.
研究的目的:
- 为了研究kaemperide的治疗潜力,一种天然的黄类,用于治疗高尿血症.
- 通过片上的脏模型探索kaemperide作用的潜在机制.
- 在HUA的背景下识别kaemperide的分子标.
主要方法:
- 利用在芯片上的平台来模拟HUA条件.
- 使用网络药理学来预测kaemperide的分子标.
- 使用免疫光和表面等离子体共振 (SPR) 确认了目标参与.
- 进行了分子对接,以阐明结合相互作用.
主要成果:
- 在片上的脏模型中,Kaemperide显著提高了细胞活力.
- 凯姆佩里德有效地缓解尿酸引起的炎症,并促进尿酸的分泌.
- 网络药理学将URAT1确定为一个关键目标,kaemperide证明了对URAT1的剂量依赖结合.
- 分子对接和实验验证证证了kaemperide和URAT1.1之间的相互作用.
结论:
- 凯姆佩里德 (Kaemperide) 成为一种潜在的新型治疗药物,用于治疗高尿血.
- 这项研究验证了片上的脏作为病研究和药物查的强大平台.
- 凯姆佩里德的机制涉及准URAT1输送器,提供一种特定的治疗方法.
相关概念视频
01:26Enhanced Elimination of Poison
Poison can be effectively removed from the gastrointestinal (GI) tract through various decontamination procedures.
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).